DoW Rare Cancers Idea Development Award
Defense Health Agency Contracting Activity - DHACA · Department of Defense · HT942526RCRPIDA
In plain English
Defense Health Agency Contracting Activity - DHACA (Department of Defense) is accepting applications for this grant until Nov 18, 2026 (7 days left).
The agency expects to make 15 awards and estimated total program funding is $7,350,000.
Eligibility is listed as unrestricted (open to any type of applicant), subject to any clarification in the listing.
The listing says cost sharing or matching is not required.
Built only from the fields in the Grants.gov listing. Always confirm on the official listing.
Key facts
| Status | Posted: open for applications |
|---|---|
| Close date | Nov 18, 2026 · 7 days left |
| Posted date | Jun 17, 2026 |
| Opportunity number | HT942526RCRPIDA |
| Agency | Defense Health Agency Contracting Activity - DHACA (Department of Defense) |
| Funding instrument | Grant |
| Category | Science and Technology and other Research and Development |
| Opportunity category | Discretionary |
| Award ceiling (max per award) | Not stated |
| Award floor (min per award) | Not stated |
| Estimated total program funding | $7,350,000 |
| Expected number of awards | 15 |
| Cost sharing or matching required | No |
| Assistance listing (CFDA/ALN) | 12.420 – Military Medical Research and Development |
| Last updated on Grants.gov | Jun 17, 2026 |
| Archive date | Dec 18, 2026 |
Who can apply
- Unrestricted (open to any type of entity above, subject to clarification in the listing)
Description
Excerpt from the official synopsis on Grants.gov (shortened; read the full text on the official listing):
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation. Distinctive Features: • The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research. • Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study. • Research should have high potential impact on rare cancers and the patient community.
More Department of Defense grants closing soon
All →- 1day leftDoW Spinal Cord Injury, Clinical Translation Research AwardUnrestricted eligibilityScience, technology and other research and development
- 1day leftDoW Spinal Cord Injury, Translational Research AwardUnrestricted eligibilityScience, technology and other research and development
- 1day leftDoW Vision, Translational Research AwardUnrestricted eligibilityScience, technology and other research and development
- 1day leftDoW Vision, Investigator-Initiated Research AwardUnrestricted eligibilityScience, technology and other research and development
More science, technology and other research and development grants closing soon
All →- 1day leftDoW Spinal Cord Injury, Clinical Trial AwardUnrestricted eligibilityScience, technology and other research and development
- 1day leftDoW Vision, Clinical Trial AwardUnrestricted eligibilityScience, technology and other research and development
- 1day leftDoW Spinal Cord Injury, Investigator-Initiated Research AwardUnrestricted eligibilityScience, technology and other research and development
- 1day leftROSES 2025: C.2 Solar System ScienceScience, technology and other research and development